1
|
Zheng Z, Liu S, Wang C, Wang C, Tang D, Shi Y, Han X. Association of genetic polymorphisms in CASP7 with risk of ischaemic stroke. Sci Rep 2019; 9:18627. [PMID: 31819117 PMCID: PMC6901581 DOI: 10.1038/s41598-019-55201-y] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/03/2019] [Accepted: 11/19/2019] [Indexed: 01/05/2023] Open
Abstract
Caspase 7 (CASP7) is located on chromosome 10q25.3 that has been identified to be a susceptibility locus of ischaemic stroke (IS) by genome-wide association study. Elevated CASP7 was observed in IS, acting as a key apoptotic mediator in the development of IS. The aim of this study was to investigate the association between genetic polymorphisms in CASP7 and risk of IS. The CASP7 polymorphisms were genotyped using a TaqMan allelic discrimination assay. The expression levels of CASP7 mRNA were examined using quantitative polymerase chain reaction and luciferase activity was analyzed using the Dual Luciferase reporter assay. The rs12415607 in the promoter of CASP7 was associated with a reduced risk of IS (AA vs. CC: adjusted OR = 0.55, 95% CI: 0.38-0.80, P = 0.002; CA/AA vs. CC: adjusted OR = 0.70, 95% CI: 0.54-0.91, P = 0.007; AA vs. CC/CA: adjusted OR = 0.64, 95% CI: 0.46-0.90, P = 0.01; A vs. C: adjusted OR = 0.74, 95% CI: 0.62-0.89, P = 0.001). Moreover, the rs12415607 AA genotype carriers exhibited lower levels of CASP7 mRNA and the rs12415607 A allele decreased the promoter activity. These findings indicate that the rs12415607 A allele induces lower levels of transcriptional activity and CASP7 mRNA, and thus is associated with a reduced risk of IS.
Collapse
Affiliation(s)
- Zhaoshi Zheng
- No. 1 Department of Neurology, China-Japan Union Hospital of Jilin University, Changchun, Jilin, 130031, P.R. China
| | - Songyan Liu
- No. 1 Department of Neurology, China-Japan Union Hospital of Jilin University, Changchun, Jilin, 130031, P.R. China
| | - Chuheng Wang
- Department of Clinical Medicine (Grade 2017 Student), School of Basic Medicine, Zhengzhou University, Zhengzhou, Henan, 450001, P.R. China
| | - Chunhui Wang
- Department of Neurosurgery, the Hospital of Jilin Province, Changchun, Jilin, 130031, P.R. China
| | - Dong Tang
- No. 1 Department of Neurology, China-Japan Union Hospital of Jilin University, Changchun, Jilin, 130031, P.R. China
| | - Yuqing Shi
- No. 1 Department of Neurology, China-Japan Union Hospital of Jilin University, Changchun, Jilin, 130031, P.R. China
| | - Xuemei Han
- No. 1 Department of Neurology, China-Japan Union Hospital of Jilin University, Changchun, Jilin, 130031, P.R. China.
| |
Collapse
|
2
|
Gao JH, Yu XH, Tang CK. CXC chemokine ligand 12 (CXCL12) in atherosclerosis: An underlying therapeutic target. Clin Chim Acta 2019; 495:538-544. [PMID: 31145896 DOI: 10.1016/j.cca.2019.05.022] [Citation(s) in RCA: 21] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/16/2019] [Revised: 05/23/2019] [Accepted: 05/24/2019] [Indexed: 12/27/2022]
Abstract
CXC chemokine ligand 12 (CXCL12) is a specific chemokine ligand and plays a significant role in cell chemotaxis. Upon binding to CXC chemokine receptor 4 (CXCR4) or CXCR7, CXCL12 can activate different signaling cascades to regulate cell proliferation, migration, and metabolism. CXCL12 exerts a pro-atherogenic action by aggravating multiple pathogenesis of atherogenesis, including dyslipidemia, inflammation, neointima hyperplasia, angiogenesis, and insulin resistance. Serum CXCL12 levels are also markedly increased in patients with atherosclerosis-associated disease. The present review focuses on recent advances in CXCL12 research in the pathogenesis of atherosclerosis together with its clinical values. This may provide insight into potential novel therapies for atherosclerosis.
Collapse
Affiliation(s)
- Jia-Hui Gao
- Institute of Cardiovascular Disease, Key Laboratory for Atherosclerology of Hunan Province, Medical Research Experiment Center, Hunan Province Cooperative Innovation Center for Molecular Target New Drug Study, University of South China, Hengyang, Hunan 421001, China
| | - Xiao-Hua Yu
- Institute of Cardiovascular Disease, Key Laboratory for Atherosclerology of Hunan Province, Medical Research Experiment Center, Hunan Province Cooperative Innovation Center for Molecular Target New Drug Study, University of South China, Hengyang, Hunan 421001, China
| | - Chao-Ke Tang
- Institute of Cardiovascular Disease, Key Laboratory for Atherosclerology of Hunan Province, Medical Research Experiment Center, Hunan Province Cooperative Innovation Center for Molecular Target New Drug Study, University of South China, Hengyang, Hunan 421001, China.
| |
Collapse
|
3
|
Jiménez-Osorio AS, Musalem-Younes C, Cárdenas-Hernández H, Solares-Tlapechco J, Costa-Urrutia P, Medina-Contreras O, Granados J, López-Saucedo C, Estrada-Garcia T, Rodríguez-Arellano ME. Common Polymorphisms Linked to Obesity and Cardiovascular Disease in Europeans and Asians are Associated with Type 2 Diabetes in Mexican Mestizos. MEDICINA (KAUNAS, LITHUANIA) 2019; 55:E40. [PMID: 30764545 PMCID: PMC6410269 DOI: 10.3390/medicina55020040] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Subscribe] [Scholar Register] [Received: 12/31/2018] [Revised: 02/03/2019] [Accepted: 02/05/2019] [Indexed: 02/07/2023]
Abstract
Background and objectives: Type 2 diabetes (T2D) is a major problem of public health in Mexico. We investigated the influence of five polymorphisms, previously associated with obesity and cardiovascular disease in Europeans and Asians, on T2D in Mexican Mestizos. Materials and Methods: A total of 1358 subjects from 30 to 85 years old were genotyped for five loci: CXCL12 rs501120; CDNK2A/B rs1333049; HNF-1α rs2259816; FTO rs9939609; and LEP rs7799039. We used logistic regressions to test the effect of each locus on T2D in two case⁻control groups with obesity and without obesity. Also, linear regression models on glucose and glycated hemoglobin (HbA1c) were carried out on the whole sample, adjusted by age, gender, and body mass index. Results: The CXCL12 rs501120 C allele (OR = 1.96, p = 0.02), the FTO rs9939609 A allele (OR = 2.20, p = 0.04) and the LEP rs7799039 A allele (OR = 0.6, p = 0.03) were significantly associated with T2D in obesity case⁻control group. No significant association was found in the non-obesity case⁻control group. The linear regression model showed that CDNK2A/B rs1333049 C allele (β = 0.4, p = 0.03) and FTO rs9939609 A allele (β = 0.5, p = 0.03), were significantly associated with HbA1c, but no association was found among the loci with the glucose levels. Conclusions: Polymorphisms previously linked with obesity and cardiovascular events were also associated with T2D and high levels of HbA1c. Furthermore, we must point at the fact that this is the first report where polymorphisms CXCL12 rs501120 and LEP rs7799039 are associated with T2D in subjects with obesity.
Collapse
Affiliation(s)
| | - Claudette Musalem-Younes
- Laboratorio de Medicina Genómica, Hospital Regional Lic. Adolfo López Mateos ISSSTE, Mexico City 01030, Mexico.
| | - Helios Cárdenas-Hernández
- Laboratorio de Medicina Genómica, Hospital Regional Lic. Adolfo López Mateos ISSSTE, Mexico City 01030, Mexico.
| | | | - Paula Costa-Urrutia
- Laboratorio de Medicina Genómica, Hospital Regional Lic. Adolfo López Mateos ISSSTE, Mexico City 01030, Mexico.
| | - Oscar Medina-Contreras
- Laboratorio de Investigación en Inmunología y Proteómica, Hospital Infantil de México Federico Gómez, Mexico City 06720, Mexico.
| | - Julio Granados
- Laboratorio de Medicina Genómica, Hospital Regional Lic. Adolfo López Mateos ISSSTE, Mexico City 01030, Mexico.
- División de Inmunogenética, Departamento de Trasplantes, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City 14080, Mexico.
| | - Catalina López-Saucedo
- Department of Molecular Biomedicine, CINVESTAV-IPN, Av. IPN #2508, Col. Zacatenco, Mexico City 07360, Mexico.
| | - Teresa Estrada-Garcia
- Department of Molecular Biomedicine, CINVESTAV-IPN, Av. IPN #2508, Col. Zacatenco, Mexico City 07360, Mexico.
| | | |
Collapse
|